How Marco Pharma International Preserves German Homeopathic Traditions in America 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
DURHAM, N.C., Nov. 10, 2017 -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the Jefferies 2017 London Healthcare Conference on Wednesday, November 15, 2017 at 8:00 a.m. GMT (3:00 a.m. EST) in London.
A live audio webcast of the event will be available via the "Investor Relations" page of the Dova website, www.dova.com. Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova's website for 90 days following the call.
About Dova Pharmaceuticals, Inc.
Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s lead drug candidate, avatrombopag, has successfully completed two pivotal Phase 3 clinical trials for the treatment of thrombocytopenia in patients with CLD scheduled to undergo a procedure and an NDA has been submitted to the FDA for this initial indication.
Contacts
Doug Blankenship
(919) 748-5975
[email protected]
Westwicke Partners
John Woolford
(443) 213-0506
[email protected]
